

---

# CNS SPECTRUMS

---

CME Review Article

**Current Management: Migraine Headache**

*This activity is provided by the Neuroscience Education Institute.*



*Additionally provided by the American Society for the Advancement of Pharmacotherapy.*



American Society for the Advancement of Pharmacotherapy  
Division 55, American Psychological Association

## CME Information

### Date of Release/Expiration

Released: December, 2017  
CME credit expires: November, 2020

### Learning Objectives

After completing this activity, you should be better able to:

- Implement evidence-based diagnostic and treatment strategies for patients with migraine designed to maximize patient outcomes
- Identify pathophysiologic targets of current and investigational therapies in migraine treatment and prevention

### Accreditation and Credit Designation Statements

The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society for the Advancement of Pharmacotherapy (ASAP), Division 55 of the American Psychological Association, is approved by the American Psychological Association to sponsor continuing education for psychologists. ASAP maintains responsibility for this program and its content.

The American Society for the Advancement of Pharmacotherapy designates this program for 1.0 CE credit for psychologists.

*Nurses and Physician Assistants:* for all of your CE requirements for recertification, the ANCC and NCCPA will accept *AMA PRA Category 1 Credits*<sup>™</sup> from organizations accredited by the ACCME. The content of this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

### Instructions for Optional Posttest and CME Credit

The estimated time for completion of this activity is 60 minutes. There is no posttest fee nor fee for CME credits.

1. Read the article
2. Complete the posttest and evaluation, available only online at [www.neiglobal.com/CME](http://www.neiglobal.com/CME) (under “CNS Spectrums”)
3. Print your certificate (passing score = 70% or higher)

Questions? call 888-535-5600, or email Customer-Service@neiglobal.com

### Peer Review

This content has been peer reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

### Disclosures

All individuals in a position to influence or control content are required to disclose any financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Disclosed financial relationships with conflicts of interest have been reviewed by the NEI CME Advisory Board Chair and resolved.

### Author

**Stephen D. Silberstein, MD**, is a professor in the Department of Neurology and the director of the Jefferson Headache Center in the Department of Neurology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. Dr. Silberstein receives research support from Lilly and is a consultant/advisor to Allergan, Amgen, Avanir, Guidepoint Global, Supernus, and Teva.

No writing assistance was utilized in the production of this article.

### CNS Spectrums Peer Review

All CME articles are peer reviewed in accordance with the strict standards of *CNS Spectrums* and in accordance with requirements and recommendations of the International Committee of Medical Journal Editors. The Editorial policies of the journal *CNS Spectrums* and peer review of all articles that appear in the journal is managed independently by Cambridge University Press and no financial relationship exists between the CME provider and Cambridge for this service.

### Additional Peer Reviewer

**Thomas L. Schwartz, MD**, is a professor in and vice chair of the Department of Psychiatry at SUNY Upstate Medical University in Syracuse, NY. Dr. Schwartz has no financial relationships to disclose.

The **Content Editor** and **Planning Committee** have no financial relationships to disclose.

### **Disclosure of Off-Label Use**

This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

### **Cultural and Linguistic Competency**

A variety of resources addressing cultural and linguistic competency can be found at this link: [www.neiglobal.com/go/cmereg](http://www.neiglobal.com/go/cmereg)

### **Provider**

This activity is provided by NEI. Additionally provided by ASAP.

### **Acknowledgment of Financial Support**

This activity is supported by an unrestricted educational grant from Lilly USA.

# Current management: migraine headache

Stephen D. Silberstein\*

Jefferson Headache Center, Philadelphia, Pennsylvania, USA

Migraine varies in its frequency, severity, and impact; treatment should consider these variations and the patient's needs and goals. Migraine pharmacologic treatment may be acute (abortive) or preventive (prophylactic), and patients often require both. New medication devices are available or in development, including an intracutaneous, microneedle system of zolmitriptan and sumatriptan, and breath-powered powder sumatriptan intranasal treatment. Lasmiditan, a 5-HT<sub>1F</sub> receptor agonist, is in development for acute treatment, as are small molecule calcitonin gene-related peptide (CGRP) receptor antagonists (Gepants) for acute and preventive treatment. Antibodies to CGRP and its receptor are being developed for migraine prevention. All 4 treatments are effective and have, as of yet, no safety concerns.

Received 27 September 2017; Accepted 6 December 2017

**Key words:** Acute treatment, headache, migraine, monoclonal antibodies, preventative treatment.

## Introduction

Migraine varies in its frequency, severity, and impact; treatment should consider these variations and the patient's needs and goals.<sup>1</sup> Treatment begins with a proper diagnosis and addressing the impact of the headache.<sup>2</sup> Education about adverse events, duration of therapy, and expectations is important.<sup>3</sup> Comorbidity is the association of two disorders more likely to occur by coincidence. Migraine comorbid disorders are listed in Table 1. Migraine treatment may be acute (abortive) or preventive (prophylactic), and patients may need both. Successful prevention reduces attack frequency. It may also decrease attack duration or severity and enhance the response to acute treatments, improve function, reduce disability,<sup>3</sup> and reduce healthcare costs.<sup>4</sup>

## Acute Treatment

Medications are usually the acute treatment of choice. In a longitudinal study, 91.7% of 11,388 people with episodic migraine reported using pharmacologic treatment for their acute migraine attacks.<sup>5</sup> The objectives of acute treatment are to treat attacks early; to achieve quick, complete pain relief; to minimize or eliminate adverse events; to restore

function; to decrease recurrence and the need for rescue treatment; and to reduce medical resource use.<sup>6</sup>

Acute pharmacologic treatment includes both migraine-specific medications, such as triptans and dihydroergotamine, and nonspecific medications such as acetylsalicylic acid (ASA), acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs). It also includes medications for relief of associated symptoms, such as nausea. Adjunctive medications include antiemetics (eg, metoclopramide or prochlorperazine) and corticosteroids.

## General Principles

1. The most effective strategy for patients with attacks of different severity is a “step care within attack” strategy. Early administration of treatment is most appropriate for consistently moderate or severe attacks that respond well to treatment. This recommendation should be guided by the frequency of the headache. For those with near-daily, daily, or continuous headache, caution is needed to avoid acute medication overuse.
2. The route of administration depends on the prior response to oral therapy, the temporal characteristics of the attack, and the presence and timing of nausea and vomiting. Early nausea and vomiting during an attack may impair absorption and bioavailability, diminishing the efficacy and/or consistency of acute medications.<sup>7</sup> Non-oral routes of administration include nasal spray, suppository, subcutaneous or transcutaneous injection, and inhalation.

\* Address for correspondence: Stephen D. Silberstein, Department of Neurology, Thomas Jefferson University, 900 Walnut Street, 2nd Floor, Ste. 200, Philadelphia, PA 19107, USA.

(Email: Stephen.Silberstein@jefferson.edu)

This activity is supported by an unrestricted educational grant from Lilly USA.

TABLE 1. Migraine comorbid disease

Cardiovascular	Neurologic
Raynaud's	Epilepsy
Patent foramen ovale (migraine with aura)	Fibromyalgia
Atrial septal defects (ASD), pulmonary AVMs	Positional vertigo
Mitral valve prolapse	Restless legs syndrome
Angina/myocardial infarction	Bell's palsy
Stroke	
<b>Psychiatric</b>	<b>GI</b>
Depression	Irritable bowel syndrome
Mania	Peptic ulcer disease
Panic disorder	
Anxiety disorder	<b>Other</b>
	Asthma
	Allergies

- Adjunctive medications are useful for patients who respond partially to a single medication. Patients who do not consistently achieve an adequate response to a triptan, for example, may require concomitant therapy to treat nausea (antiemetic), or to achieve a more sustained response by reducing the risk of recurrence within a 24- to 48-hour period (NSAID).<sup>8–11</sup>
- All patients need rescue therapy when acute therapy is not effective, even if they typically respond to their usual treatment.<sup>12–15</sup>

### Acute Treatment Guidelines

According to an evidence-based guideline from the American Headache Society (Table 2), all currently available triptans, in various formulations, are effective (Level A) for the acute treatment of migraine for moderate or severe pain at the time of treatment. Dihydroergotamine nasal spray is effective (Level A), and ergotamine and intravenous ergotamine are probably effective (Level B) for acute treatment.

Effective nonspecific medications include aspirin (500 mg), acetaminophen (1000 mg), diclofenac (50 or 100 mg), ibuprofen, metamizole (dipyrone) (1 mg), naproxen (500 or 550 mg), rofecoxib (25 mg), butorphenol nasal spray, codeine, and a combination of acetaminophen/aspirin/caffeine (Level A). Ketoprofen, IV ketorolac, or magnesium; isometheptene compounds; and tramadol/acetaminophen are probably effective (Level B). There is not enough information available to determine if celecoxib (400 mg) is effective in migraine (Level U). The antiemetics prochlorpromazine, droperidol, chlorpromazine, and metoclopramide are probably effective (Level B).

Dexamethasone is probably effective when given with rizatriptan (10 mg) (Level B). There is inadequate evidence for intravenous valproic acid (Level U). Butalbital is possibly effective (Level C).

### Emerging Acute Therapies

While the triptans have significantly advanced acute migraine treatment, approximately one-fifth of migraineurs have cardiovascular contraindications that limit their use. Their efficacy is limited when considering the most robust patient-centered outcomes. In addition, triptans induce latent central sensitization and may promote the development of medication overuse headache (MOH).<sup>16</sup> Therefore, there is a large unmet treatment need for safe and effective acute migraine drugs that do not constrict vascular beds or induce MOH. In addition, new formulations of older drugs are being developed. U.S. Food and Drug Administration (FDA)-approved new formulations include sumatriptan needle-free injection (brand name Sumavel); sumatriptan epipen-like injection (brand name Alsuma); sumatriptan auto-injectors (Dr. Reddy's Zembrace, Sun, generic); and breath-powered powder sumatriptan intranasal treatment (brand name Onzetra).

Sumatriptan iontophoretic patch (brand name Zecuity) is off the market because of adverse events (AEs). Awaiting FDA approval are rizatriptan dissolvable film (RHB-103, VersaFilm) and dihydroergotamine (DHE) oral inhalation (brand name Semprana).

New medication devices in development include an intracutaneous microneedle system of zolmitriptan<sup>17</sup> and sumatriptan (Sofusa Dose Disc System Skin Patch), zolmitriptan oral inhalation (CVT-427), and sumatriptan oral spray (SUD-001).

### 5-HT<sub>1F</sub> Receptor Agonists

Serotonin (5-hydroxytryptamine [5-HT]), a biogenic amine, was identified, crystallized, and named by Rapport and Page.<sup>18</sup> There are 7 types of 5-HT receptors, 5-HT<sub>1–7</sub>. All are G protein-coupled receptors except the 5-HT<sub>3</sub> receptor, which is a ligand-gated cation channel.<sup>19</sup> The 5-HT<sub>1</sub> subfamily consists of 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1E</sub>, and 5-HT<sub>1F</sub>.<sup>19</sup>

Ergotamine targets 5-HT<sub>1A–1F</sub>; 5-HT<sub>2A–C</sub>, D<sub>1–5</sub> and  $\alpha$ 1 and  $\alpha$ 2 adrenergic receptor types.<sup>20</sup> The anti-migraine effects are due to agonist activity at the 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, and possibly 5-HT<sub>1F</sub> receptors on trigeminal nerve terminals.<sup>21</sup> Ergotamine causes vasoconstriction, which can cause hypertension and coronary vasoconstriction. Retroperitoneal fibrosis, pleuropulmonary fibrosis, and cardiac valvulopathy can occur with chronic use.

The triptans have high 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor affinity. 5-HT<sub>1B</sub> receptors mediate vasoconstriction, and 5-HT<sub>1D</sub> receptors mediate inhibition of neuronal impulse transmission.<sup>11</sup> In addition, several triptans have affinity for the 5-HT<sub>1F</sub> receptors subtype, which does not mediate vasoconstriction.<sup>22</sup> Spiral and vestibular ganglion cells in rodents and primates express the

TABLE 2. Acute treatment evidence

Level A	Level B	Level C	Level U	Others
<b>Analgesic</b> Acetaminophen 1000 mg (for non-incapacitating attacks)	<b>Antiemetics</b> *Chlorpromazine IV 12.5 mg Droperidol IV 2.75 mg *Metoclopramide IV 10 mg *Prochlorperazine IV/IM 10 mg; PR 25 mg	<b>Antiepileptic</b> Valproate IV 400-1000 mg	<b>NSAIDs</b> Celecoxib 400 mg	<b>Level B negative</b> <b>Other</b> Octreotide SC 100 µg
<b>Ergots</b> DHE *Nasal spray 2 mg Pulmonary inhaler 1 mg	<b>Ergots</b> DHE * IV, IM, SC 1 mg *Ergotamin/caffeine 1/100 mg	<b>Ergot</b> *Ergotamine 1-2 mg	<b>Others</b> *Lidocaine IV *Hydrocortisone IV 50 mg	<b>Level C negative</b> <b>Antiemetics</b> *Chlorpromazine IM 1 mg/kg *Granisetron IV 40-80 µg/kg <b>NSAIDs</b> Ketorolac tromethamine nasal spray
<b>NSAIDs</b> *Aspirin 500 mg Diclofenac 50, 100 mg Ibuprofen 200, 400 mg *Naproxen 500, 550 mg	<b>NSAIDs</b> *Flurbiprofen 100 mg Ketoprofen 100 mg Ketorolac IV/IM 30-60 mg	<b>NSAIDs</b> Phenazone 1000 mg		
<b>Opioids</b> *Butorphanol nasal spray 1 mg		<b>Opioid</b> *Butorphanol IM 2 mg *Codeine 30 mg PO *Meperidine IM 75 mg *Methadone IM 10 mg *Tramadol IV 100 mg		<b>Analgesic</b> Acetaminophen IV 1000 mg
<b>Triptans</b> Almotriptan 12.5 mg Eletriptan 20, 40, 80 mg Frovatriptan 2.5 mg *Naratriptan 1, 2.5 mg *Rizatriptan 5, 10 mg Sumatriptan *Oral 25, 50, 100 mg *Nasal spray 10, 20 mg Patch 6.5 mg *SC 4, 6 mg Zolmitriptan nasal spray 2.5, 5 mg *Oral 2.5, 5 mg	<b>Others</b> MgSO <sub>4</sub> IV (migraine with aura) 1-2 g *Isometheptene 65 mg	<b>Steroid</b> Dexamethasone IV 4-16 mg		
<b>Combinations</b> *Acetaminophen/aspirin/caffeine 500/500/130 mg Sumatriptan/naproxen 85/500 mg	<b>Combinations</b> *Codeine/acetaminophen 25/400 mg Tramadol/acetaminophen 75/650 mg	<b>Others</b> *Butalbital 50 mg *Lidocaine intranasal  <b>Combinations</b> *Butalbital/acetaminophen/caffeine/codeine 50/325/40/30 mg *Butalbital/acetaminophen/caffeine 50/ 325/40 mg		

Level A: Medications are established as effective for acute migraine treatment based on available evidence. Level B: Medications are probably effective for acute migraine treatment based on available evidence. Level C: Medications are possibly effective for acute migraine treatment based on available evidence. Level U: Evidence is conflicting or inadequate to support or refute the efficacy of the medications for acute migraine. Level B negative: Medication is probably ineffective for acute migraine. Level C negative: Medication is possibly ineffective for acute migraine. NS = nasal spray.

5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1F</sub> receptors. Hence, actions of ganglion cells might partly explain the efficacy of these agents in vestibular migraine and their vestibular AEs.<sup>23</sup>

Lasmiditan (COL-144) is a highly selective, potent 5-HT<sub>1F</sub> receptor agonist.<sup>24</sup> In preclinical animal models, it inhibited dural plasma protein extravasation and

reduced trigeminal nucleus caudalis c-Fos expression, following trigeminal ganglion stimulation.<sup>25</sup> Lasmiditan had no vasoconstrictor effect on the rabbit saphenous vein.<sup>25</sup> An intravenous formulation was effective in a proof-of-concept, dose-finding study. Intravenous lasmiditan, at a starting dose of 2.5 mg, was evaluated for the acute treatment of migraine in 130 subjects in a hospital

setting.<sup>24</sup> Forty-two subjects received placebo and 88 received lasmiditan, in doses ranging from 2.5–45 mg. Of subjects treated in the 10, 20, 30, and 45 mg lasmiditan dose groups, 54–75% showed a 2-hour headache response, compared to 45% in the placebo group ( $P < 0.0126$ ). AEs occurred in 65% of lasmiditan and in 43% of placebo subjects. Dizziness, paresthesia, and limb heaviness occurred more often with lasmiditan.

Oral lasmiditan (50, 100, 200, and 400 mg) was studied in a multicenter, double-blind, parallel-group, dose-ranging, acute migraine study.<sup>26</sup> Lasmiditan was superior to placebo, and showed a dose response effect at 2 hours. Treatment-emergent AEs were dose-dependent, and mild or moderate in intensity. Adverse events included vertigo, dizziness, paresthesia, fatigue, and somnolence.

Controlled phase 3 trials have been completed.<sup>27</sup> In the SAMURAI trial, 2,231 patients were randomized to lasmiditan (100 mg, 200 mg) or placebo; a second dose was permitted for rescue or recurrence. The primary endpoint was 2-hour pain freedom. The key secondary endpoint was the relief of the most bothersome symptoms (MBS) at 2 hours (before dosing, subjects noted whether nausea, phonophobia, or photophobia were present and which was “most bothersome”). About half of subjects found photophobia was their MBS (about one-quarter for nausea and vomiting). For the groups lasmiditan 100 mg, lasmiditan 200 mg, and placebo, 28.2%, 32.2%, and 15.3%, respectively, were free of pain at 2 hours and 40.9%, 40.7%, and 29.5%, respectively, were free of MBS at 2 hours (all  $< 0.001$  compared to placebo). Headache pain relief was 59.4%, 59.5%, and 42.2%, respectively ( $p < 0.001$ ). AEs were dose-dependent and included vertigo, dizziness, paresthesia, fatigue, and somnolence. In this trial, lasmiditan met its primary and secondary endpoints, and many subjects had cardiovascular risk factors or conditions. The GLADIATOR phase 3 long-term, open-label trial is ongoing.<sup>28</sup>

The SPARTAN trial, in addition to 100 mg and 200 mg lasmiditan groups, included a 50 mg group to find the lowest effective dose in acute migraine.<sup>26</sup> The primary and secondary outcome measures are like those of the SAMURAI trial. This trial was completed in June 2017.<sup>29</sup>

### CGRP Receptor Antagonists (Gepants)

The CGRP family of neuropeptides consists of CGRP, calcitonin (CT), adrenomedullin (AM), and amylin (AMY). Human CGRP comes in 2 types:  $\alpha$  and  $\beta$ .  $\alpha$ -CGRP results from alternative splicing of the calcitonin gene; it is the main subtype in trigeminal neurons.<sup>30</sup> The canonical CGRP receptor has three parts: (1) calcitonin-like receptor, (2) receptor activity-modifying protein type 1, and (3) a receptor component protein.<sup>31</sup> CGRP

receptors are present on trigeminal ganglia, primary dural sensory afferents, the periaqueductal gray (PAG), and on meningeal blood vessels.<sup>30</sup> The adrenomedullin receptors, AM1 and AM2, consist of CLR coupled with either RAMP2 or RAMP3, respectively. The calcitonin receptor (CTR) consists of only CTR. Amylin receptors are created by linking CTR with a RAMP; amylin AMY1-3 receptors consist of CTR plus RAMP1, 2, or 3, respectively. The amylin 1 receptor (CTR with RAMP1) also responds to CGRP.<sup>32</sup>

CGRP is important in migraine pathophysiology. CGRP infusion triggers attacks of migraine that are indistinguishable from spontaneous attacks in migraineurs<sup>33</sup>; triptans inhibit the release of CGRP<sup>34</sup>; migraine pain relief parallels the decline in circulating CGRP levels<sup>35</sup>; and its levels are increased in external jugular venous blood during an acute migraine attack.<sup>35</sup> The most compelling pieces of evidence are the results of several trials that evaluated the selective CGRP receptor antagonists (gepants) for acute migraine treatment. Gepants are not vasoconstrictors and have minimal adverse events. Gepants block both the canonical CGRP receptor and the Amylin 1 receptor. Five gepants are effective for acute migraine treatment.<sup>36–40</sup> Olcegepant, while effective, could only be given intravenously and was abandoned.<sup>38</sup> Olcegepant (2.5 mg IV) had a response rate of 66%, compared with 27% for placebo. Telcagepant (orally available) had 6 positive phase III trials.<sup>30,41,42</sup> AEs were similar to placebo, but it acted slower than triptans: 26% of subjects were pain free at 2 hours; placebo 11%; rizatriptan (10 mg) 41%; and almotriptan (12.5 mg) 35%.<sup>42</sup> Telcagepant development has been stopped because of significant elevations in liver transaminase levels. Another gepant, MK-3207, was terminated because of asymptomatic liver enzyme abnormalities.<sup>39</sup> Boehringer Ingelheim compared BI 44370 TA<sup>37</sup> (50, 200, and 400 mg) to eletriptan (40 mg) and placebo. More patients had pain freedom at 2 hours, which was significant in the 400 mg group (27.4 %) and the eletriptan group (34.8 %), compared to placebo. BMS-927711 (10, 25, 75, 150, 300, or 600 mg) was tested in a double-blind, placebo-controlled, dose-ranging study<sup>40</sup> using an adaptive design in comparison to sumatriptan 100 mg or placebo. Significantly more patients in the BMS-927711 75 mg (31.4%,  $p < 0.002$ ), 150 mg (32.9%,  $p < 0.001$ ), and 300 mg (29.7%,  $p < 0.002$ ) groups and the sumatriptan group (35%,  $p < 0.001$ ) were free of pain at 2 hours compared to placebo (15.3%). No serious treatment-related AEs were reported, and no patients discontinued because of AEs. Biohaven has acquired BMS-927711 (now called rimegepant) for acute migraine and BHV-3500 for migraine prevention from Bristol-Myers Squibb Company.

Recently Allergan acquired 2 CGRP small molecule receptor antagonists from Merck: ubrogepant

(MK-1602) for acute migraine treatment and atogepant (MK-8031) for migraine prevention. These different chemical entities are believed to not cause the liver AEs of prior gepants. Voss *et al*<sup>43</sup> studied ubrogepant for the acute migraine treatment in a Phase 2b randomized, double-blind, placebo-controlled trial. Ubrogepant (1 mg, 10 mg, 25 mg, 50 mg, 100 mg) was compared to placebo in a 1:1 ratio. Ubrogepant 100 mg was significantly superior to placebo for pain freedom (25.8% versus 8.9%), but not for headache response at 2 hours. Overall AEs were similar to placebo. Further trials are underway. In aggregate, these studies confirm that gepants are effective for acute migraine treatment and, like lasmiditan, lack vasoconstrictor activity.

## Preventive Treatment

### Principles

Recent guidelines<sup>44–49</sup> have established criteria for considering migraine preventive treatments and their efficacy (Table 3):

1. Disabling attacks despite appropriate acute treatment
2. Frequency ( $\geq 4$  attacks or  $\geq 8$  headache days/month)
3. Acute treatment failure, overuse, or bothersome AEs
4. Patient choice
5. Hemiplegic migraine; basilar migraine; frequent, prolonged, or uncomfortable aura symptoms; or migrainous infarction<sup>44,45,50</sup>

A preventive treatment is successful when it decreases migraine by half.

### General guidelines for instituting preventive therapy

- Start at a low dose and slowly increase until it is effective, the maximum dose is reached, or there are intolerable AEs.
- Consider comorbidity disorders (Table 1).<sup>46,51–58</sup>
- Do not use contraindicated drugs (coexistent or comorbid illnesses).
- Have an adequate trial (2–6 months).
- Have realistic goals.
- Periodically reevaluate therapy.
- Women need to be aware of drug effects on a fetus.<sup>59</sup>
- Involve patients; discuss their treatment and their expectations.
- Discuss AEs.

Monotherapy is a treatment goal but is often not attainable. Polytherapy may enable therapeutic adjustments based on the status of coexistent disorders.

## New Preventive Medications

### Small molecule CGRP antagonists (gepants)

Gepants block both the canonical CGRP receptor and the amylin 1 receptor. Ho *et al*<sup>60</sup> evaluated telcagepant in a migraine preventive trial. The trial was terminated due to hepatotoxicity concerns. Telcagepant was effective, but the aminotransferase elevations led to its discontinuation. Allergan acquired the rights to 2 new CGRP small molecule receptor antagonists from Merck, including atogepant (MK-8031), for the prevention of migraines. Biohaven acquired 2 new gepants from

TABLE 3. Classification of migraine preventive therapies

Level A: Effective	Level B: Probably effective	Level C: Possibly effective	Level U: Inadequate or conflicting data	Ineffective, probably or possibly effective
<b>AEDs</b>	<b>Antidepressants</b>	<b>ACE inhibitors</b>	<b><math>\alpha</math>-Agonists</b>	<b>Ineffective</b>
Divalproex sodium	Amitriptyline	Lisinopril	Clonidine	Lamotrigine
Sodium valproate	Venlafaxine	<b>Angiotensin blockers</b>	<b>Antidepressants</b>	<b>Probably ineffective</b>
Topiramate	<b><math>\beta</math>-Blockers</b>	Candesartan	Fluoxetine	Clomipramine
<b><math>\beta</math>-Blockers</b>	Atenolol	<b>AEDs</b>	Fluvoxamine	<b>Possibly ineffective</b>
Metoprolol	Nadolol	Carbamazepine	Protriptyline	Acebutolol
Propranolol		<b>Antihistamines</b>	<b>AEDs</b>	Clonazepam
Timolol		Cyproheptadine	Gabapentin	Nabumetone
		<b><math>\beta</math>-Blockers</b>	<b><math>\beta</math>-Blockers</b>	Oxcarbazepine
		Nebivolol	Bisoprolol	Telmisartan
			Pindolol	
			<b>Ca ++ blockers</b>	
			Cyclandelate	
			Nicardipine	
			Nifedipine	
			Nimodipine	
			Verapamil	

Abbreviations: ACE = angiotensin-converting-enzyme; Ca ++ blockers = calcium channel blockers; MRM = menstrually related migraine; SSNRI = selective serotonin–norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

Bristol-Myers Squibb Company including BHV-3500 for migraine prevention.

### Monoclonal antibodies (mABs)

Monoclonal antibodies (mABs) to CGRP and its receptor now exist. How do they differ from small molecules? MABs function extracellularly, while small molecules function both extra- and intracellularly. They are more specific, do not affect QT intervals, and have limited, off-target toxicity. They do not cross the blood–brain barrier and have few central nervous system AEs. mABs are large molecules and cannot be administered orally. Their half-life is weeks, allowing for long-dosing intervals. They are not eliminated through the liver or kidneys. Humanized mABs contain 85% to >90% human protein. Fully human or human mABs contain both heavy and light chains from human origins.<sup>61</sup>

Three mABs that target CGRP, and one that targets the canonical CGRP receptor, are being developed. Lilly is developing Galcanezumab (LY2951742), a humanized monoclonal antibody against CGRP. Galcanezumab blocks capsaicin-induced increases in skin blood flow. Capsaicin stimulates dermal neurons to release CGRP, resulting in increased dermal blood flow. CGRP mAB receptor antagonist effects last for at least a week.<sup>62</sup> The time to Cmax after subcutaneous (SC) ranges from 7 to 13 days, with a 28 days elimination half-life. A phase 2 study in episodic migraine has been completed. Patients (18–65) were randomly assigned (1:1) to galcanezumab (n = 108) or placebo (n = 110) (SC) every 2 weeks for 12 weeks. The primary endpoint (mean change migraine headache days/28-day period) was assessed at 9–12 weeks. The mean change in migraine headache days was –4.2 (SD 3.1; 62.5% decrease), with galcanezumab group compared with –3.0 (SD 3.0; 42.3% decrease) with placebo. AEs more frequent than placebo included injection site pain, erythema, upper respiratory tract infections, and abdominal pain. Galcanezumab thus is beneficial in migraine prevention and provides support for the role of CGRP in the pathogenesis of migraine.<sup>63</sup> There are a number of ongoing trials:

- EVOLVE-2 study (NCT02614196): a phase 3, randomized, D-B, P-C study in episodic migraine
- REGAIN study (NCT02614261): a phase 3, randomized, D-B, P-C study in chronic migraine
- Studies in episodic (NCT02397473) and chronic (NCT02438826) cluster headache<sup>64</sup>

Teva acquired fremanezumab (TEV-48125, formerly LBR-101) from Labrys. It is a humanized mAB against isoforms ( $\alpha$  and  $\beta$ ) of CGRP.<sup>65</sup> In phase 1 studies, it was given to 94 subjects (0.2–2000 mg) once (day 1) intravenously (IV), or up to 300 mg given twice (day 1 and day 14). The drug was very well-tolerated, with about

1.4 treatment-emergent AEs compared to 1.3 on placebo. Overall treatment-related AEs occurred in 21.2% of the active group and in 17.7% of the placebo group.

Bigal *et al*<sup>66</sup> studied fremanezumab in the prevention of high-frequency episodic migraine (phase 2b). They randomly assigned patients to 3 28-day treatment cycles of subcutaneous (SC) fremanezumab (225 mg or 675 mg) or placebo. Migraine days decreased from baseline to weeks 9–12 by –3.46 days in the placebo group, compared to –6.27 days for 225 mg, and –6.09 days for the 675 mg group. In this trial, fremanezumab was safe, well-tolerated, and effective as a preventive treatment of high-frequency episodic migraine.<sup>66</sup> Bigal *et al* then studied 2 doses of fremanezumab in chronic migraine prevention. They randomly assigned patients to 3 28-day treatment cycles of SC fremanezumab (675 mg in the first and 225 mg in the second and third treatment cycles), fremanezumab (900 mg each treatment cycle), or placebo. The mean decrease from baseline in headache-hours during weeks 9–12 was –59.84 hours in the 675/225 mg group, –67.51 hours in the 900 mg group, compared to –37.10 hours for placebo. Most AEs were mild (injection-site pain and pruritus). Fremanezumab SC was tolerable and effective.<sup>67</sup>

Trials underway include the following:

- A multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens for episodic migraine prevention (NCT02629861)
- A second study for chronic migraine prevention (NCT02621931)
- A randomized, double-blind, placebo-controlled, parallel-group study of 2 dose regimens for episodic cluster headache prevention (NCT02945046)
- A second study for chronic cluster headache (NCT02964338)<sup>64</sup>

Alder developed eptinezumab (ALD403) a desialylated, humanized IgG1 mAB that binds to both  $\alpha$  and  $\beta$  forms of human CGRP. The plasma elimination after T<sub>1/2</sub> is 31 days. Dodick *et al*<sup>68</sup> studied eptinezumab for migraine prevention in a phase 2 trial. Patients (18–55) who had 5 to 14 migraine days/28-days were randomized to IV eptinezumab 1000 mg or placebo. Safety was assessed 12 weeks later. The primary endpoint was the change from baseline to weeks 5–8 in migraine day frequency. AEs occurred in 57% of patients in the eptinezumab group and 52% in the placebo group. The mean change in migraine days was –5.6 (SD 3.0) for the eptinezumab group compared with –4.6 (3.6) for placebo (difference –1.0, 95% CI –2.0 to 0.1; one-sided p = 0.0306). No safety issues were found. In this study, eptinezumab was effective in high-frequency, episodic migraine prevention.

Dodick *et al*<sup>69</sup> studied single IV infusions of eptinezumab 300 mg, 100 mg, 30 mg, and 10 mg versus placebo in the prevention of chronic migraine. Subjects were randomized, and received either a single infusion of eptinezumab 300 mg, 100 mg, 30 mg, 10 mg, or placebo by a 1-hour IV infusion. The study met the primary 12-week post-infusion efficacy endpoint: % difference in patients achieving a 75% reduction in migraine days from baseline: eptinezumab 300 mg (33%) and 100 mg (31%) versus placebo (21%) (weeks 1–12). Significantly more patients had a 50% reduction in migraine days from baseline for eptinezumab 300 mg, 100 mg, and 30 mg versus placebo (weeks 1–12). Eptinezumab was safe, well-tolerated, and met the primary endpoint of  $\geq 75\%$  reduction in migraine days compared to placebo.

Erenumab (AMG 334), developed by Amgen, is a human mAb of the IgG2 subtype against the canonical CGRP receptor, not CGRP. The CGRP receptor is a G protein-coupled receptor that is composed of the calcitonin receptor-like receptor and receptor activity-modifying protein 1 (RAMP1) subunits. Erenumab has high affinity (Kd 20 pM) competitively and reversible receptor binding. Its estimated elimination  $T_{1/2}$  is 21 days.

Sun *et al*<sup>70</sup> studied erenumab in migraine prevention in a double-blind, placebo-controlled, phase 2 trial. Patients (18–60) who had 4 to 14 migraine days per month were randomized (3:2:2:2 ratio) to monthly SC placebo, erenumab 7 mg, 21 mg, or 70 mg. The primary endpoint, the mean change in monthly migraine days (baseline to the last 4 weeks of the 12-week, double-blind treatment phase), was  $-3.4$  days with erenumab 70 mg versus  $-2.3$  days with placebo (difference  $-1.1$  days,  $p=0.021$ ). The mean reductions in monthly migraine days with the 7 mg ( $-2.2$ ) and the 21 mg ( $-2.4$ ) doses were not significantly different from placebo. AEs occurred in 54% of those who received placebo compared to 50% to 54% in the erenumab groups. Erenumab 70 mg is a potential therapy for prevention of episodic migraine. Two trials are underway for erenumab in episodic migraine prevention: ARISE (NCT02483585) and STRIVE (NCT02456740).<sup>64</sup>

Tepper *et al*<sup>71</sup> studied erenumab in subjects with chronic migraine (18–65 years). Patients received erenumab (70 mg or 140 mg) or placebo every month by SC injection. The primary endpoint was the change from baseline in monthly migraine days. The secondary endpoints were the proportion of patients with  $\geq 50\%$  reduction in monthly migraine days, change from baseline in acute migraine-specific medication use days, and change from baseline in cumulative headache hours. Both erenumab doses [70 mg ( $-6.64$ ) and 140 mg (16.63)] had statistically significant clinically meaningful reduction in monthly migraine days compared with placebo ( $-4.8$ ). Erenumab 70 mg (39.9%) and 140 mg

(41.1%) also showed statistically significant improvements in  $\geq 50\%$  responder rate compared to placebo (23.5%). Safety and tolerability were like placebo. One trial is underway for erenumab in chronic migraine prevention (NCT20120295).<sup>64</sup>

### Orexin receptor antagonists (orexants)

The orexins (A and B) are a pair of hypothalamic neuropeptides that may be involved in nociception. Both neuropeptides are cleaved from the same precursor, preproorexin, and act on 2 G-coupled receptors termed the orexin 1 (OX1R) and 2 (OX2R) receptors. Orexin A shows equal efficacy for both receptors, while orexin B is relatively selective for the OX2R. Filorexant, a dual orexin receptor antagonist, was not effective in a phase 2a trial for migraine prevention.<sup>72</sup> However, preclinical evidence suggests that orexin A is anti-nociceptive, whereas orexin B was pro-nociceptive. Perhaps antagonism of the OX2R or agonism of the OX1R may be beneficial.<sup>73</sup>

### Nitric oxide synthase inhibitors (NOS)

NOS produces nitric oxide triggering CGRP release. NOS inhibitors (neuronal and inducible) were not effective for acute or preventive migraine treatment.<sup>74,75</sup>

### Botulinum toxin (BoNT) for migraine

Seven BoNT serotypes (A, B, C1, D, E, F, and G) are produced by *Clostridium botulinum*. All inhibit acetylcholine release, but they differ in targets, characteristics, and potencies.<sup>76,77</sup> Botulinum toxin type A (BoNTA) is the most commonly studied serotype.<sup>76</sup> BoNT is available as onabotulinumtoxinA (botulinum toxin type A), abobotulinumtoxinA (another type A), and rimabotulinumtoxinB.

BoNT is approved for chronic migraine prevention and may be effective in high-frequency episodic migraine. The mechanism of action of BoNT in headache is still uncertain.

## Conclusion

Pharmacologic treatment is a cornerstone of migraine management. Preventive medication can not only reduce attack frequency, but can also improve acute treatment response and quality of life. Many migraine patients need prevention, but few get it. Many preventive medications are available, and guidelines for their selection and use have been established. Comorbid medical and psychological illnesses must be considered when choosing preventive drugs,<sup>75</sup> but there are no characteristics predictive of response to acute or preventive treatment.

## Disclosures

Stephen Silberstein has the following disclosures: Allergan, consultant/advisor; Amgen, consultant/advisor; Avanir Pharmaceuticals, consultant/advisor; Guidepoint Global, consultant/advisor; Lilly USA, research grant; Supernus Pharmaceuticals, consultant/advisor; Teva Pharmaceutical Industries, consultant/advisor.

## REFERENCES:

- Silberstein SD. Migraine. *Lancet*. 2004; **363**(9406): 381–391.
- Silberstein SD, Saper JR, Freitag F. Migraine: diagnosis and treatment. In Silberstein SD, Lipton RB, Dalessio DJ, eds. *Wolff's Headache and Other Head Pain*, 7th ed. New York: Oxford University Press; 2001: 121–237.
- Lipton RB, Silberstein SD. Why study the comorbidity of migraine? *Neurology*. 1994; **44**(17): 4–5.
- Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. *Headache*. 2003; **43**(3): 171–178.
- Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study. *Headache*. 2012; **52**(2): 213–223.
- Silberstein SD. Practice parameter—evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. *Neurology*. 2000; **55**(6): 754–762.
- Aurora S, Kori S, Barrodale P, Nelsen A, McDonald S. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. *Headache*. 2007; **47**(10): 1443–1446.
- Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. *Headache*. 2005; **45**(7): 850–861.
- Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. *JAMA*. 2007; **297**(13): 1443–1454.
- Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. *Neurology*. 2008; **71**(2): 114–121.
- Rapoport AM. Acute treatment of headache. *J Headache Pain*. 2006; **7**(5): 355–359.
- Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. *Clin Pharmacol Ther*. 2013; **93**(1): 78–85.
- Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. *Headache*. 2006; **46**(5): 773–780.
- Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. *Can J Neurol Sci*. 2015; **40**(S3): S1–S3.
- Bigal ME, Ho TW. Is there an inherent limit to acute migraine treatment efficacy? *J Headache Pain*. 2009; **10**(6): 393–394.
- De FM, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. *Brain*. 2010; **133**(Pt 8): 2475–2488.
- Kellerman D, Lickliter J, Mardell J, von Stein T. Pharmacokinetics and tolerability of a new intracutaneous microneedle system of zolmitriptan (ZP-zolmitriptan). *PF01 AHS San Diego*. 2016: 2016.
- Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. *J Biol Chem*. 1948; **176**(3): 1243–1251.
- McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. *Pharmacol Ther*. 2015; **150**: 129–142.
- Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. *Headache*. 1997; **37**(Suppl 1): S15–S25.
- Ramírez Rosas MB, Labrujere S, Villalón CM, Maassen VanDenBrink A. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. *Expert Opin Pharmacother*. 2013; **14**(12): 1599–1610.
- Ramadan NM, Skljarevski V, Phebus LA, Johnson KW. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. *Cephalalgia*. 2003; **23**(8): 776–785.
- Furman JM, Marcus DA, Balaban CD. Vestibular migraine: clinical aspects and pathophysiology. *Lancet Neurol*. 2013; **12**(7): 706–715.
- Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. *Cephalalgia*. 2010; **30**(10): 1170–1178.
- Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. *Cephalalgia*. 2010; **30**(10): 1159–1169.
- Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. *Lancet Neurol*. 2012; **11**(5): 405–413.
- CoLucid Pharmaceuticals. SAMURAI—pivotal phase 3 clinical trial conducted under SPA (special protocol assessment). European Headache and Migraine Trust International Congress. Glasgow, UK; 2016.
- CoLucid Pharmaceuticals. An open-label, long-term, safety study of lasmiditan for the acute treatment of migraine (GLADIATOR). October 1, 2015. <https://clinicaltrials.gov/ct2/show/NCT02565186>.
- CoLucid Pharmaceuticals. Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). November 16, 2015. <https://clinicaltrials.gov/ct2/show/NCT02605174>.
- Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. *Nat Rev Neurol*. 2010; **6**(10): 573–582.
- Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. *BMC Neurosci*. 2011; **12**: 112.
- Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? *Br J Pharmacol*. 2013; **170**(7): 1293–1307.
- Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. *Cephalalgia*. 2010; **30**(10): 1179–1186.
- Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. *Pain*. 2012; **153**(4): 830–838.
- Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. *Cephalalgia*. 1991; **11**(11 Suppl 1): 3–4.
- Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. *Lancet*. 2008; **372**(9656): 2115–2123.
- Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. *Cephalalgia*. 2011; **31**(5): 573–584.

38. Olesen J, Diener HC, Husstedt IW, *et al.* Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *N Engl J Med.* 2004; **350**(11): 1104–1110.
39. Hewitt DJ, Aurora SK, Dodick DW, *et al.* Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. *Cephalalgia.* 2011; **31**(6): 712–722.
40. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. *Cephalalgia.* 2014; **34**(2): 114–125.
41. Ho AP, Dahlof CG, Silberstein SD, *et al.* Randomized, controlled trial of telcagepant over four migraine attacks. *Cephalalgia.* 2010; **30**(12): 1443–1457.
42. Tfelt-Hansen P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. *Headache.* 2011; **51**(1): 118–123.
43. Voss T, Lipton RB, Dodick DW, *et al.* A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. *Cephalalgia.* 2016; **36**(9): 887–898.
44. Silberstein SD. Headaches in pregnancy. *Neurol Clin.* 2004; **22**(4): 727–756.
45. Lipton RB, Diamond M, Freitag F, Bigal M, Stewart WF, Reed ML. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. *Headache.* 2005; **45**(6): 792–793.
46. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology.* 2012; **78**(17): 1337–1345.
47. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology.* 2012; **78**(17): 1346–1353.
48. Pringsheim T, Davenport W, Mackie G, *et al.* Canadian Headache Society guideline for migraine prophylaxis. *Can J Neurol Sci.* 2012; **39**(2 Suppl 2): S1–S59.
49. Carville S, Padhi S, Reason T, Underwood M. Diagnosis and management of headaches in young people and adults: summary of NICE guidance. *BMJ.* 2012; **345**: e5765.
50. Lipton RB, Bigal M, Diamond M. Migraine prevalence, disease burden and the need for preventive therapy. *Neurology.* 2007; **68**(5): 343–349.
51. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. *Headache.* 1986; **26**(10): 490–493.
52. Ryan RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. *Headache.* 1983; **23**(1): 26–31.
53. Ryan RE. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. *Am Heart J.* 1984; **108**(4): 1156–1159.
54. Sudilovsky A, Stern MA, Meyer JH. Nadolol: the benefits of an adequate trial duration in the prophylaxis of migraine. *Headache.* 1986; **26**(6): 325.
55. Ifergane G, Buskila D, Simiseshvely N, Zeev K, Cohen H. Prevalence of fibromyalgia syndrome in migraine patients. *Cephalalgia.* 2006; **26**(4): 451–456.
56. Saunders K, Merikangas K, Low NC, Von Korff M, Kessler RC. Impact of comorbidity on headache-related disability. *Neurology.* 2008; **70**(7): 538–547.
57. Schwedt TJ. The migraine association with cardiac anomalies, cardiovascular disease, and stroke. *Neurol Clin.* 2009; **27**(2): 513–523.
58. Schoenen J, Dodick DW, Sandor PS. *Comorbidity in Migraine.* Sussex, UK: Wiley Blackwell; 2011.
59. Silberstein SD. Migraine and pregnancy. *Neurol Clin.* 1997; **15**(1): 209–231.
60. Ho TW, Connor KM, Zhang Y, *et al.* Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. *Neurology.* 2014; **83**(11): 958–966.
61. Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. *Headache.* 2015; **55**(8): 1171–1182.
62. Zhu DXD, Zhang J, Zhou L, *et al.* A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys. American Headache Society 54th Annual Scientific Meeting, Los Angeles, CA, 6/21/12.
63. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Neurol.* 2014; **13**(9): 885–892.
64. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention. [www.clinicaltrials.gov/ct2/show/NCT02066415](http://www.clinicaltrials.gov/ct2/show/NCT02066415).
65. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. *Headache.* 2013; **53**(8): 1230–1244.
66. Bigal ME, Dodick DW, Rapoport AM, *et al.* Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol.* 2015; **14**(11): 1081–1090.
67. Bigal ME, Edvinsson L, Rapoport AM, *et al.* Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol.* 2015; **14**(11): 1091–1100.
68. Dodick DW, Goadsby PJ, Silberstein SD, *et al.* Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. *Lancet Neurol.* 2014; **13**(11): 1100–1107.
69. Dodick D, Silberstein S, Lipton R, *et al.* Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine. European Headache and Migraine Trust International Congress Glasgow, UK; 2016.
70. Sun H, Dodick DW, Silberstein S, *et al.* Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2016; **15**(4): 382–390.
71. Tepper S, Ashina M, Reuter U, *et al.* Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol.* 2017; **16**(6): 425–434.
72. Chabi A, Zhang Y, Jackson S, *et al.* Randomized controlled trial of the orexin receptor antagonist florexant for migraine prophylaxis. *Cephalalgia.* 2015; **35**(5): 379–388.
73. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. *Pain.* 2004; **109**(3): 367–378.
74. Hoivik HO, Laurijssens BE, Harnisch LO, *et al.* Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. *Cephalalgia.* 2010; **30**(12): 1458–1467.
75. Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. *Cephalalgia.* 2009; **29**(1): 124.
76. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes; a comparative review of biochemical and pharmacological actions. *Eur J Neurol.* 2001; **8**(Suppl 5): 21–29.
77. Mauskop A. The use of botulinum toxin in the treatment of headaches. *Pain Physician.* 2004; **7**: 377–387.

## Optional Posttest and CME Certificate

*CME Credit Expires: November 30, 2020*

### Posttest Study Guide

**NOTE: The posttest can only be submitted online.** The below posttest questions have been provided solely as a study tool to prepare for your online submission. **Faxed/mailed copies of the posttest cannot be processed** and will be returned to the sender. If you do not have access to a computer, contact NEI customer service at 888-535-5600.

1. According to treatment guidelines, ergotamine is considered:
  - A. Effective (Level A)
  - B. Probably effective (Level B)
  - C. Possibly effective (Level C)
  - D. Unknown (Level U)
2. Lasmiditan, in Phase 3 trials for the treatment of acute migraine, acts at what receptors?
  - A. 5HT1B
  - B. 5HT1F
  - C. 5HT2C
  - D. 5HT3
3. Preventive treatment for migraine is considered successful when it reduces migraine by:
  - A. One third
  - B. One half
  - C. Two thirds
  - D. Three fourths
4. Monoclonal antibodies (mABs) to CGRP and its receptors function:
  - A. Extracellularly
  - B. Intracellularly
  - C. Both extra- and intracellularly

### Optional Online Posttest and CME Certificate Instructions

There is no posttest fee nor fee for CME credits.

1. Read the article.
2. Complete the posttest and evaluation, available only online at [www.neiglobal.com/CME](http://www.neiglobal.com/CME) (under “CNS Spectrums”).
3. Print your certificate (passing score = 70% or higher).

Questions? call 888-535-5600, or email [CustomerService@neiglobal.com](mailto:CustomerService@neiglobal.com)

